ClinicalTrials.gg

Program

HS-10582

A development code.

In Hansoh Pharmaceutical Group's pipeline, hypercholesterolaemia. Its studies are mostly in Dyslipidemias, led by Hansoh Pharmaceutical Group.

Furthest: phase 1, since Jul 31, 20261 company-led study, 1 open or runningNext primary completion: May 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group11 open or runningphase 1since Jul 31, 2026Jul 31, 2026May 30, 2027phase 1 · NCT07777003
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-10582 (hypercholesterolaemia), phase 1, as of Aug 26, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 31, 2026First study: phase 1 study in DyslipidemiasFirst studyNCT07777003 · 76 planned

Ahead

  1. May 30, 2027Primary completion: phase 1 study in DyslipidemiasNCT07777003

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“hypercholesterolaemia”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07777003Dyslipidemias1Not yet recruitingMay 30, 202776

How it is read

Names in the registry

  • “HS-10582”, 1 entry

Codes read as this program: HS10582.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.